Clinical Trials · NCT00630695

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

CompletedPhase 3Lanreotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
University Hospital, Limoges
Enrollment
148
Start date
Mar 2008
Locations
1 site, France
Primary endpoint
Quantity of lymph collected by the drain
View Lanreotide compound reference